1. Home
  2. PUBM vs CGEM Comparison

PUBM vs CGEM Comparison

Compare PUBM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$9.21

Market Cap

406.5M

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.66

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
CGEM
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
406.5M
671.7M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PUBM
CGEM
Price
$9.21
$10.66
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$18.45
$27.14
AVG Volume (30 Days)
1.1M
1.3M
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$288,382,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.01
$5.68
52 Week High
$17.32
$13.60

Technical Indicators

Market Signals
Indicator
PUBM
CGEM
Relative Strength Index (RSI) 54.40 58.77
Support Level $8.91 $10.01
Resistance Level $9.24 $13.33
Average True Range (ATR) 0.35 1.07
MACD -0.00 -0.00
Stochastic Oscillator 61.62 47.06

Price Performance

Historical Comparison
PUBM
CGEM

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: